Precision oncology is transforming cancer treatment by replacing broad trial-and-error approaches with individualized therapies based on tumor biology. This article compares chemotherapy and ... Aug 10
Precision oncology is transforming cancer care by shifting from traditional trial-and-error treatments to personalized therapies based on each patient’s unique molecular profile. ... Jul 04
Takeover to advance T-Cell Activator Solid Tumor Treatments and expand new Cancer Immunotherapy Portfolio... Mar 13
Sorrento receives USFDA clearance to start a clinical trial of Anti-CD47 Antibody, discovered from fully human G-MAB library, for treatment of multiple malignancies ... Mar 03
Compugen Ltd expands collaboration agreement with Bristol Myers Squibb with phase 1b combination study of COM701 with opdivo C... Feb 22
Blueprint Medicines requested priority review for this application, which, if granted, could result in a six-month review process... Dec 18
The two partners want to pool their expertise in order to identify and develop new monoclonal antibodies for cancer therapy... Nov 24
Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today declared their 4th and full year report.... Feb 21
-Advertisements-
.jpeg)
Wednesday, September 30, 2026
.png)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)